AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 211 min read$MED

Kiai Parsa purchased $843K of MED (indirect holdings)

Kiai Parsa purchased 72,487 indirectly-held shares of MEDIFAST INC (MED) at an average of $11.63 ($11.60–$11.66, $0.84M total) across 4 trades over 2026-08-19 to 2026-08-20.

Original reporting
SEC EDGAR · Kiai Parsa
Published Aug 21, 2026, 4:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 4:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MED
Neutral
medium confidence
Mentioned
$MED
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDNeutralLow
01

Why it matters

The purchase adds modest confidence but unlikely to move the stock significantly.

02

Market read

Small insider buy; limited immediate trading relevance.

03

What to watch

Potential upcoming product launch or earnings could be the real driver.

Relevance 6/10Novelty 7/10Timing: filing today

Background

Form 4 filing discloses insider transactions; MED is a US-listed consumer health company.

Company-level read

Ticker impact

$MEDNeutralMedium confidence
Context

Director Kiai Parsa bought 72,487 shares of Medifast for $842,699, increasing his stake to 18,977 shares.

Expected impact

Potential slight upside pressure; limited impact.

Evidence & confidence

Purchase amount under $1M and indirect ownership suggest modest market reaction.

Market effects

Sector

Minimal effect on consumer health sector.

Regional

No regional impact.

Global

Limited to Medifast investors.

Counterpoint

What could challenge this read

Insider purchase may be routine portfolio rebalancing, not a strong buy signal.

Key entities

  • Director
    Kiai Parsa

    Director of Medifast who purchased shares.

  • Company
    Medifast Inc

    US-listed consumer health company (ticker MED).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MED insider trading history →

Related articles

AUG 4
$MEDHighAI 9/10

Why Medifast (MED) Stock Is Trading Up Today

Medifast (NYSE: MED) shares rose 37.5% after Q2 results beat expectations and the company issued a stronger full-year outlook. Medifast reported a $0.28 per-share loss versus a $0.65 expected loss, and revenue of $76.38 million. It guided full-year GAAP EPS of $1.00 at the midpoint, versus analyst estimates.

financialcontent.com4 min
AUG 3
$MEDMed

MEDIFAST INC (MED): Results of Operations and Financial Condition

MEDIFAST INC (MED) filed an SEC Form 8-K — Results of Operations and Financial Condition. Medifast Announces Second Quarter 2026 Financial Results August 3, 2026 BALTIMORE – ( BUSINESS WIRE ) — Medifast (NYSE: MED), the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, today reported results for the second quarter

SEC EDGAR 8-K6 min